Gastroenterology

Multiplex PCR panel tests for viral and gastrointestinal pathogens as well as the rapid identification of bloodstream infections can detect more pathogens more quickly than traditional microbiology methods. However, the panels come at a high price. A recent CAP TODAY article highlighted industry experts’ opinion on the clinical use of these panels, including Robin Patel, M.D., Chair of the Division of Clinical Microbiology and a Consultant in the Clinical Microbiology and Infectious Diseases Laboratories at Mayo Clinic.

By Kelley Luedke • February 10, 2016

Helicobacter pylori (H pylori) infection is among the most common bacterial infections worldwide with approximately one-half of the world’s population infected. Several invasive and noninvasive testing methods are available to detect H pylori infection.

By Communiqué Archive • January 15, 2016

Several multiplex molecular assays have been developed for the detection of gastrointestinal pathogens directly from clinical stool samples. These panels allow for the detection and identification of up to 20 pathogens in as little as one hour. A recent review published in the Journal of Clinical Microbiology focuses on the FDA-cleared multiplex molecular panels for the diagnosis of diarrheal disease and highlights issues related to test performance, result interpretation, and cost-effectiveness of these molecular diagnostic tools.

By Kelley Luedke • November 12, 2015

Up to 30 percent of patients with diarrheal irritable bowel syndrome (IBS) also suffer from bile acid malabsorption (BAM). Recently, a new test was introduced that can identify BAM from a stool sample. In this “Hot Topic,” Leslie Donato, Ph.D., will describe a new test for probing the etiology of this condition.

By MCL Education • August 3, 2015

Diagnosis of idiopathic duct-centric chronic pancreatitis (IDCP), also known as type 2 autoimmune pancreatitis, requires pancreatic histology and/or concurrent inflammable bowel disease. In a recent study published in the journal Gut, Mayo Clinic researchers examined past experience with IDCP to assess the appropriateness of this criteria, and identify unique characteristics in patients presenting with acute pancreatitis.

By Kelley Luedke • July 15, 2015

Learn what’s new, view our featured GI testing resources, and if you’re attending, visit us at booth #3425.

By brentwestra • May 15, 2015

The new Infliximab Quantitation with Reflex to Antibodies to Infliximab, Serum, test is now available to the Mayo Clinic practice and Mayo Medical Laboratories clients. This test should be ordered to assess a trough level quantitation for evaluation of patients with loss of response to infliximab.

By brentwestra • May 13, 2015

Mayo Clinic researchers conducted a recent study in Gastroenterology to investigate whether gut-derived murine stem cells for interstitial cells of Cajal could mitigate experimental colitis.

By Kelley Luedke • March 4, 2015

Mayo Clinic researchers conducted a study published in the American Journal of Gastroenterology, to determine whether patients with multifocal polysomy are more likely to manifest cholangiocarcinoma compared with patients with other chromosomal abnormalities, including unifocal polysomy and other FISH subtypes.

By Kelley Luedke • February 17, 2015

A recent article in The New York Times reported on celiac disease, an autoimmune disorder of the gut triggered by the gluten proteins in wheat and other grains, and its connection to the human brain. Upon analysis of several cases, treating an autoimmune disease of the gut (by avoiding gluten) resolved what looked like a debilitating disorder of the brain.

By Kelley Luedke • October 13, 2014

On Monday, August 11, the Food and Drug Administration announced its approval of the first stool-based colorectal screening test co-developed by Exact Sciences and Mayo Clinic. Exact Sciences will be the sole provider of this new test. While the test is based on Mayo Clinic research, the test will not be available through Mayo Medical Laboratories.

By Andy Tofilon • August 13, 2014

Chronic hepatitis C virus (HCV) is the primary cause of cirrhosis, hepatocellular carcinoma (HCC), and end-stage liver disease requiring liver transplantation. Mayo Medical Laboratories offers an assay for use to confirm the presence of chronic HCV infection, to determine pretreatment (baseline) HCV RNA levels in serum, and to monitor a patient’s response to antiviral therapy.

By Kelley Luedke • July 1, 2014

In this 6-part “Hot Topic” series, Glenn Roberts, Ph.D., discusses the distribution and ecology of histoplasmosis, blastomycosis, and coccidioidomycosis fungi, as well as their pathogenesis and cultural characteristics.

By MCL Education • February 28, 2014